Publicaciones Similares
Biosimilars in Argentina
The country is currently an important producer of biopharmaceuticals, and for this reason, there are incentivization policies for the development of biosimilars…
Biosimilars in Latin America
The regulations for biosimilars vary
considerably from one country to
another, but in general the trend is an
increase in the regulatory standards for their health registration.
Rare Diseases – Orphan drugs- innovative- models of procurement for rare diseases- pricing and reimbursement in Latin America
Orphan drugs used to treat rare diseases have been labeled “orphan drugs” because of their applicability to very small populations, and they respond to public health needs
Oppotunities for orphan drugs in Latin America
There are ample opportunities for the entry of orphan drugs into the region. The size of the Latin American orphan drug market was USD 14.17 billion in 2021 and it is estimated that it will increase by 7.38% by 2026. Based on the type of drug, the biological sector dominates the orphan drug market for Latin America
What is the inflation reduction act?
An In-Depth Examination of the Inflation Reduction Act: Unraveling its Purpose, Goals, and Impact on the Pharmaceutical Sector. Delve into the intricacies of this legislative initiative, understanding its imperative role in mitigating inflationary pressures. Navigate through the refined landscape of the pharmaceutical market, appreciating the nuanced changes implemented to fortify economic stability and foster enduring industry prosperity.
Health System in Argentina
To ensure compliance with area policies for the promotion, preservation, and recovery of the population’s health, strengthening the balance between users, providers, and financiers, in conditions of free
competition, transparency, economic efficiency, and social equity.